Perindoprilat (BioDeep_00000014088)

 

Secondary id: BioDeep_00000408946

human metabolite Endogenous blood metabolite


代谢物信息卡片


(2S,3aS,7aS)-1-[(2S)-2-{[(1S)-1-carboxybutyl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid

  化学式: C17H28N2O5 (340.1998)
中文名称: 培哚普利
  谱图信息: 最多检出来源 Homo sapiens(blood) 20.69%

分子结构信息

SMILES: CCCC(C(=O)O)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O
InChI: InChI=1S/C17H28N2O5/c1-3-6-12(16(21)22)18-10(2)15(20)19-13-8-5-4-7-11(13)9-14(19)17(23)24/h10-14,18H,3-9H2,1-2H3,(H,21,22)(H,23,24)/t10-,11-,12-,13-,14-/m0/s1


描述信息

Perindoprilat is a metabolite of perindopril. Perindopril, or perindopril arginine, (trade names include Coversyl and Aceon) is a long-acting ACE inhibitor. Perindopril is used to treat high blood pressure, heart failure or stable coronary artery disease. It is also available in a generic form, perindopril erbumine. (Wikipedia)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents

同义名列表

44 个代谢物同义名

(2S,3aS,7aS)-1-[(2S)-2-{[(1S)-1-carboxybutyl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid; (2S,3AS,7as)-1-[(2S)-2-{[(1S)-1-carboxybutyl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-{[(1S)-1-carboxybutyl]amino}propanoyl]-octahydroindole-2-carboxylic acid; (2S,3AS,7as)-1-[(2S)-2-{[(1S)-1-carboxybutyl]amino}propanoyl]octahydro-1H-indole-2-carboxylate; Perindoprilic acid; Perindoprilatum; Perindoprilato; SCHEMBL1269121; Perindoprilate; Perondropilat; Perindoprilat; S-9780; S 9780; X94; (2S,3aS,7aS)-1-(((S)-1-carboxybutyl)-L-alanyl)octahydro-1H-indole-2-carboxylic acid; (2S,3aS,7aS)-1-((2S)-2-(((1S)-1-carboxybutyl)amino)propanoyl)octahydro-1H-indole-2-carboxylic acid; (2S,3aS,7aS)-1-((S)-2-(((S)-1-carboxybutyl)amino)propanoyl)octahydro-1H-indole-2-carboxylic acid; (2S,3aS,7aS)-1-((S)-2-(((S)-1-carboxybutyl)amino)propanoyl)octahydro-1H-indole-2-carboxylicacid; (2S,3aS,7aS)-1-((S)-N-((S)-1-Carboxybutyl)alanyl)hexahydro-2-indolinecarboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-Carboxybutyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic Acid; (2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-carboxybutyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-Carboxybutyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic Acid (Perindoprilat); (2s,3as,7as)-1-[(2s)-2-[[(2s)-1-hydroxy-1-oxopentan-2-yl]amino] propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-{[(1S)-1-carboxybutyl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid (non-preferred name); [2S-[1[R*(R*)],2alpha,3abeta,7abeta]]-1-[2-[(1-Carboxybutyl)amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic Acid; 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-carboxybutyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-; 1H-Indole-2-carboxylic acid, 1-[2-[(1-carboxybutyl)amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2a,3ass,7ass]]-; Perindoprilat; S 9780; Perindopril RC B;; 1H-Indole-2-carboxylic acid, octahydro-1-(2-((1-carboxybutyl)amino)-1-oxopropyl)-, (2S-(1(R*(R*)),2-alpha,3a-beta,7a-beta))-; 2UV6ZNQ92K; A1-06488; N-((2S)-1-((2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl)-1-oxopropan-2-yl)-L-norvaline; N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline; Perindopril diacid form; PERINDOPRIL DIACID FORM [MI]; PERINDOPRIL TERT-BUTYLAMINE IMPURITY B (EP IMPURITY); PERINDOPRIL TERT-BUTYLAMINE IMPURITY B [EP IMPURITY]; Perindoprilat [INN:BAN]; PERINDOPRILAT [INN]; Perindoprilate [French]; Perindoprilato [Spanish]; Perindoprilatum (Latin); Perindoprilatum [Latin]; Perondroprilat; UNII-2UV6ZNQ92K



数据库引用编号

12 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome()

BioCyc()

PlantCyc()

代谢反应

1 个相关的代谢反应过程信息。

Reactome()

BioCyc()

WikiPathways()

Plant Reactome()

INOH()

PlantCyc()

COVID-19 Disease Map()

PathBank(1)

PharmGKB()

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Xin Zheng, Huitao Gao, Xinge Cui, Yanbao Zhang, Rui Chen, Yaqin Wang, Pauline Lauruol, Hongyun Wang. Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2021 Apr; 1169(?):122585. doi: 10.1016/j.jchromb.2021.122585. [PMID: 33706186]
  • Yuxiu Gu, Hualin Cai, Jianjun Guo, Xiaomei Huang, Heng Yang, Yamin Yin, Xun Tan, Binbin He, Xiaomeng Zhou, Xia Liu, Wei Wei, Bikui Zhang. A UPLC-MS/MS method for quantification of perindopril and perindoprilat and applied in a bioequivalence study for their pharmacokinetic parameter measurement
. International journal of clinical pharmacology and therapeutics. 2020 Feb; 58(2):103-111. doi: 10.5414/cp203593. [PMID: 31845865]
  • Catherine Leggett, Ei Mon Phyo Lwin, Usha Ritchie, Yunmei Song, Jacobus P Gerber, Sean Turner, William M Hague, Michael Stark, Richard Upton, Sanjay Garg. Perindopril in Breast Milk and Determination of Breastfed Infant Exposure: A Prospective Observational Study. Drug design, development and therapy. 2020; 14(?):961-967. doi: 10.2147/dddt.s239704. [PMID: 32184565]
  • Ei Mon Phyo Lwin, Cobus Gerber, Yunmei Song, Catherine Leggett, Usha Ritchie, Sean Turner, Sanjay Garg. A new LC-MS/MS bioanalytical method for perindopril and perindoprilat in human plasma and milk. Analytical and bioanalytical chemistry. 2017 Oct; 409(26):6141-6148. doi: 10.1007/s00216-017-0552-y. [PMID: 28842738]
  • Sofia Georgakakou, Michael Kazanis, Irene Panderi. Hydrophilic interaction liquid chromatography/positive ion electrospray ionization mass spectrometry method for the quantification of perindopril and its main metabolite in human plasma. Analytical and bioanalytical chemistry. 2010 Jul; 397(6):2161-70. doi: 10.1007/s00216-010-3551-9. [PMID: 20195579]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Deepak S Jain, Gunta Subbaiah, Mallika Sanyal, Umesh C Pande, Pranav Shrivastav. First LC-MS/MS electrospray ionization validated method for the quantification of perindopril and its metabolite perindoprilat in human plasma and its application to bioequivalence study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Jun; 837(1-2):92-100. doi: 10.1016/j.jchromb.2006.04.008. [PMID: 16709467]
  • Izabella Z A Pawluczyk, Samita R Patel, Kevin P G Harris. The role of bradykinin in the antifibrotic actions of perindoprilat on human mesangial cells. Kidney international. 2004 Apr; 65(4):1240-51. doi: 10.1111/j.1523-1755.2004.00494.x. [PMID: 15086463]
  • Shigeki Yamada, Isao Muraoka, Kana Kato, Yoko Hiromi, Rie Takasu, Hachiro Seno, Hirohisa Kawahara, Toshitaka Nabeshima. Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biological & pharmaceutical bulletin. 2003 Jun; 26(6):872-5. doi: 10.1248/bpb.26.872. [PMID: 12808303]
  • Anne Prévot, Frédéric Huet, Denis S Semama, Jean-Bernard Gouyon, Jean-Pierre Guignard. Complementary effects of adenosine and angiotensin II in hypoxemia-induced renal dysfunction in the rabbit. Life sciences. 2002 Jul; 71(7):779-87. doi: 10.1016/s0024-3205(02)01768-x. [PMID: 12074937]
  • Kohji Takara, Mikio Kakumoto, Yusuke Tanigawara, Junko Funakoshi, Toshiyuki Sakaeda, Katsuhiko Okumura. Interaction of digoxin with antihypertensive drugs via MDR1. Life sciences. 2002 Feb; 70(13):1491-500. doi: 10.1016/s0024-3205(01)01494-1. [PMID: 11895100]
  • H Nagashima, Y Sakomura, Y Aoka, K Uto, Kameyama Ki, M Ogawa, S Aomi, H Koyanagi, N Ishizuka, M Naruse, M Kawana, H Kasanuki. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation. 2001 Sep; 104(12 Suppl 1):I282-7. doi: 10.1161/hc37t1.094856. [PMID: 11568070]
  • E Bellissant, J F Giudicelli. Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients. British journal of clinical pharmacology. 2001 Jul; 52(1):25-33. doi: 10.1046/j.0306-5251.2001.01410.x. [PMID: 11453887]
  • P Tóth-Heyn, D Mosig, J P Guignard. Chronic bradykinin receptor blockade modulates neonatal renal function. Biology of the neonate. 2000; 77(1):45-9. doi: 10.1159/000014194. [PMID: 10658830]
  • J B Su, F Barbe, B Crozatier, D J Campbell, L Hittinger. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. Journal of cardiovascular pharmacology. 1999 Nov; 34(5):700-10. doi: 10.1097/00005344-199911000-00012. [PMID: 10547087]
  • A Piasecka, K Marciniak, M Koter, E Krajewska, W Leyko, M Bryszewska. Interaction of perindoprilat with human red blood cells. Scandinavian journal of clinical and laboratory investigation. 1999 Apr; 59(2):147-52. doi: 10.1080/00365519950185887. [PMID: 10353329]
  • F Huet, D S Semama, J B Gouyon, J P Guignard. Protective effect of perindoprilat in the hypoxemia-induced renal dysfunction in the newborn rabbit. Pediatric research. 1999 Jan; 45(1):138-42. doi: 10.1203/00006450-199901000-00023. [PMID: 9890622]
  • Y Yang, G J Macdonald. Development of a new assay for measurement of total angiotensin-converting enzyme after inhibition. Clinical and experimental pharmacology & physiology. 1998 Jul; 25(7-8):637-9. doi: 10.1111/j.1440-1681.1998.tb02268.x. [PMID: 9673444]
  • A N Orekhov, V V Tertov, E M Pivovarova. The effects of antihypertensive agents on atherosclerosis-related parameters of human aorta intimal cells. Cardiology. 1998; 89(2):111-8. doi: 10.1159/000006765. [PMID: 9524011]
  • P Tóth-Heyn, D Mosig, J P Guignard. Role of bradykinin in the neonatal renal effects of angiotensin converting enzyme inhibition. Life sciences. 1998; 62(4):309-18. doi: 10.1016/s0024-3205(97)01112-0. [PMID: 9450502]
  • I Antony, A Nitenberg. [Coronary endothelial dysfunction in hypertension]. Archives des maladies du coeur et des vaisseaux. 1997 Nov; 90 Spec No 6(?):21-7. doi: ". [PMID: 9515110]
  • F Huet, J B Gouyon, J P Guignard. Prevention of hypoxemia-induced renal dysfunction by perindoprilat in the rabbit. Life sciences. 1997; 61(22):2157-65. doi: 10.1016/s0024-3205(97)00918-1. [PMID: 9393935]
  • H Hickey, M Makdissi, R Hyland, D Wilks, G J Dusting. Perindopril treatment prevents the loss of endothelial nitric oxide function and development of neo-intima in rabbits. Journal of molecular and cellular cardiology. 1996 Sep; 28(9):1985-94. doi: 10.1006/jmcc.1996.0191. [PMID: 8899557]
  • I B Squire, R J MacFayden, J L Reid, A Devlin, K R Lees. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. Journal of cardiovascular pharmacology. 1996 May; 27(5):657-66. doi: 10.1097/00005344-199605000-00007. [PMID: 8859935]
  • P J Anderson, J A Critchley, B Tomlinson, G Resplandy. Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. British journal of clinical pharmacology. 1995 Apr; 39(4):361-8. doi: 10.1111/j.1365-2125.1995.tb04463.x. [PMID: 7640141]
  • R J MacFadyen, K R Lees, J L Reid. Responses to low dose intravenous perindoprilat infusion in salt deplete/salt replete normotensive volunteers. British journal of clinical pharmacology. 1994 Oct; 38(4):329-34. doi: 10.1111/j.1365-2125.1994.tb04362.x. [PMID: 7833222]
  • P A Fennessy, J H Campbell, G R Campbell. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis. 1994 Mar; 106(1):29-41. doi: 10.1016/0021-9150(94)90080-9. [PMID: 8018105]
  • R B Perich, B Jackson, C I Johnston. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. European journal of pharmacology. 1994 Feb; 266(3):201-11. doi: 10.1016/0922-4106(94)90128-7. [PMID: 8174603]
  • U Zwettler, D Fliser, M Nowicki, E Ritz. OACE inhibition does not interfere with acute extrarenal or renal potassium disposal in chronic renal failure. European journal of clinical pharmacology. 1994; 46(3):185-9. doi: 10.1007/bf00192546. [PMID: 8070497]
  • J L Reid, R J MacFadyen, I B Squire, K R Lees. Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose. American heart journal. 1993 Sep; 126(3 Pt 2):794-7. doi: 10.1016/0002-8703(93)90932-y. [PMID: 8395761]
  • M Huijberts, B Wolffenbuttel, F Crijns, A N Kruseman, M Bemelmans, H Van Essen, J Smits, H S Boudier. Inhibition of angiotensin-converting enzyme reduces urinary albumin excretion but not regional albumin clearance in experimental diabetes. European journal of pharmacology. 1993 Aug; 240(2-3):207-12. doi: 10.1016/0014-2999(93)90900-3. [PMID: 8243539]
  • E Rondeau, F Paillard, M N Peraldi, I Violet, S Tasse, J C Dussaule, R Ardaillou, J D Sraer. Role of the renin-angiotensin system on the renal functional reserve in renal transplant recipients. Kidney international. 1993 Jul; 44(1):165-72. doi: 10.1038/ki.1993.227. [PMID: 8355458]
  • J L Reid, R J MacFadyen, I B Squire, K R Lees. Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. The American journal of cardiology. 1993 Jun; 71(17):57E-60E. doi: 10.1016/0002-9149(93)90954-b. [PMID: 8392282]
  • R J MacFadyen, K R Lees, J L Reid. Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure. British heart journal. 1993 Apr; 69(4):293-7. doi: 10.1136/hrt.69.4.293. [PMID: 8387806]
  • F Bree, P Nguyen, S Urien, G Resplandy, J P Tillement. Specific and high affinity binding of perindoprilat, but not of perindopril to blood ACE. International journal of clinical pharmacology, therapy, and toxicology. 1992 Sep; 30(9):325-30. doi: . [PMID: 1330941]
  • R J MacFadyen, K R Lees, J L Reid. Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers. British journal of clinical pharmacology. 1992 Aug; 34(2):115-21. doi: 10.1111/j.1365-2125.1992.tb04119.x. [PMID: 1419473]
  • C A Muller, L H Opie, M Peisach, C A Pineda. Antiarrhythmic effects of the angiotensin converting enzyme inhibitor perindoprilat in a pig model of acute regional myocardial ischemia. Journal of cardiovascular pharmacology. 1992 May; 19(5):748-54. doi: NULL. [PMID: 1381773]
  • M Thiollet, C Funck-Brentano, J D Grangé, M Midavaine, G Resplandy, P Jaillon. The pharmacokinetics of perindopril in patients with liver cirrhosis. British journal of clinical pharmacology. 1992 Mar; 33(3):326-8. doi: 10.1111/j.1365-2125.1992.tb04045.x. [PMID: 1576057]
  • J Sennesael, A Ali, P Sweny, M Vandenburg, D Slovic, M Dratwa, G Resplandy, P Genissel, P Desche. The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure. British journal of clinical pharmacology. 1992 Jan; 33(1):93-9. doi: 10.1111/j.1365-2125.1992.tb04006.x. [PMID: 1311597]
  • R J MacFadyen, K R Lees, J D Gemmill, W S Hillis, J L Reid. Transpulmonary pharmacokinetics of an ACE inhibitor (perindoprilat) in man. British journal of clinical pharmacology. 1991 Aug; 32(2):193-9. doi: 10.1111/j.1365-2125.1991.tb03881.x. [PMID: 1657093]
  • G A Verpooten, P M Genissel, J R Thomas, M E De Broe. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. British journal of clinical pharmacology. 1991 Aug; 32(2):187-92. doi: 10.1111/j.1365-2125.1991.tb03880.x. [PMID: 1657092]
  • F A Mendelsohn, V Pupic, B Jackson, R Cubela, C I Johnston. Acute and chronic effects of perindopril on tissue angiotensin converting enzyme activity. American journal of hypertension. 1991 Mar; 4(3 Pt 2):220S-225S. doi: 10.1093/ajh/4.3.220s. [PMID: 1645981]
  • H van den Berg, G Resplandy, A T de Bie, W Floor, M Bertrand, C J Arts. A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity. Journal of pharmaceutical and biomedical analysis. 1991; 9(7):517-24. doi: 10.1016/0731-7085(91)80172-6. [PMID: 1817672]
  • G Resplandy, P Genissel. Pharmacokinetics of perindopril in high-risk populations. Journal of cardiovascular pharmacology. 1991; 18 Suppl 7(?):S9-18. doi: NULL. [PMID: 1725203]
  • C L Brown, C I Backhouse, J C Grippat, J P Santoni. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. European journal of clinical pharmacology. 1990; 39(4):327-32. doi: 10.1007/bf00315404. [PMID: 2076713]
  • J P Devissaguet, N Ammoury, M Devissaguet, L Perret. Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundamental & clinical pharmacology. 1990; 4(2):175-89. doi: 10.1111/j.1472-8206.1990.tb00486.x. [PMID: 2351367]
  • K R Lees, A W Kelman, J L Reid, B Whiting. Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. Journal of pharmacokinetics and biopharmaceutics. 1989 Oct; 17(5):529-50. doi: 10.1007/bf01071348. [PMID: 2559190]
  • P Omvik, P Lund-Johansen. Acute haemodynamic effects of perindoprilat in essential hypertension at rest and during exercise. Journal of hypertension. 1989 Aug; 7(8):633-8. doi: 10.1097/00004872-198908000-00006. [PMID: 2681409]
  • K R Lees, D M Hughes, C A McNeill, J L Reid. Pharmacokinetics of perindopril: therapeutic consequences. Archives des maladies du coeur et des vaisseaux. 1989 May; 82 Spec No 1(?):31-4. doi: NULL. [PMID: 2505711]
  • C Tsaconas, M Devissaguet, P Padieu. Gas chromatography-mass spectrometry of perindopril and its active free metabolite, an angiotensin convertase inhibitor: choice of derivatives and ionization modes. Journal of chromatography. 1989 Mar; 488(1):249-65. doi: 10.1016/s0378-4347(00)82950-3. [PMID: 2715284]
  • M Schmidt, J P Krieger, M Devissaguet, J L Imbs. Renal effects of perindoprilat, an angiotensin-converting enzyme inhibitor, in the anesthetized dog. Journal of cardiovascular pharmacology. 1989 Feb; 13(2):283-90. doi: 10.1097/00005344-198902000-00017. [PMID: 2468959]
  • K R Lees, A W Kelman, B Whiting, J L Reid. Indirect assessment of tissue angiotensin II converting enzyme inhibition in vivo in man. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1988 Dec; 6(3):S55-6. doi: NULL. [PMID: 3225689]
  • K R Lees, J L Reid. Effects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects. Journal of cardiovascular pharmacology. 1987 Aug; 10(2):129-35. doi: 10.1097/00005344-198708000-00001. [PMID: 2441162]